Literature DB >> 15713991

Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency.

Argiris Symeonidis1, Alexandra Kouraklis-Symeonidis, Dimitris Apostolopoulos, Evangelia Arvanitopoulou, Nikolaos Giannakoulas, Pavlos Vassilakos, Nicholas Zoumbos.   

Abstract

OBJECTIVES: To estimate the usefulness of serum tumor markers' monitoring, as predictors of gastric cancer in patients with pernicious anemia. PATIENTS AND METHODS: We investigated serum levels of carcinoembryonic antigen (CEA), alpha-fetal protein, cancer antigen (CA)-19.9, CA-125 and CA-15.3 in 50 patients with pernicious anemia and in 24 healthy controls, matched for age and sex. In 38 patients, the evaluation was repeated 1-6 months after the correction of cobalamin deficiency.
RESULTS: All patients and controls had normal serum CEA and alpha-FP, and the levels of these markers as well as those of CA-125 and CA-19.9 did not differ between the two groups. All 50 patients, but only 2 controls exhibited increased serum CA-15.3, and the difference between the two groups was very significant (129.4 +/- 84.9 vs. 19.8 +/- 7.3 IU/ml, p < 0.001), while no difference between males and females was found. A thorough clinical examination of all patients, and mammographic study in 18 females did not reveal any finding suspicious of breast cancer. CA-15.3 levels were positively correlated with serum lactate dehydrogenase, and negatively with B(12) and hemoglobin, but they were substantially decreased after the correction of anemia, in all 38 patients tested, and in 33 of them they were restored to normal. After a median follow-up of 34 months, one patient developed a colon cancer, but none showed any sign suspicious of breast cancer.
CONCLUSIONS: Serum CA-15.3 shows an aberrant increase in untreated patients with pernicious anemia, which is reversed after the correction of the anemia. The possible origin seems unrelated to mammary tissue, and may be released by the apoptosing bone marrow megaloblastic erythroblasts. Copyright (c) 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15713991     DOI: 10.1159/000082919

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  4 in total

1.  Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site.

Authors:  Rafael Molina; Xavier Bosch; Josep M Auge; Xavier Filella; José M Escudero; Víctor Molina; Manel Solé; Alfonso López-Soto
Journal:  Tumour Biol       Date:  2011-12-09

2.  Do serum biomarkers really measure breast cancer?

Authors:  Jonathan L Jesneck; Sayan Mukherjee; Zoya Yurkovetsky; Merlise Clyde; Jeffrey R Marks; Anna E Lokshin; Joseph Y Lo
Journal:  BMC Cancer       Date:  2009-05-28       Impact factor: 4.430

3.  Spurious laboratory alterations in pernicious anemia.

Authors:  Adriana Isabel Dias Roque; Cláudia Nadine da Silva; Joana Maria Dos Reis Mata Albuquerque Martins; Maria Amélia Fonseca Pereira
Journal:  Rev Bras Hematol Hemoter       Date:  2015-08-17

4.  Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence.

Authors:  Yayoi Adachi; Toyone Kikumori; Noriyuki Miyajima; Takahiro Inaishi; Eiji Onishi; Masahiro Shibata; Kenichi Nakanishi; Dai Takeuchi; Hironori Hayashi; Yasuhiro Kodera
Journal:  Surg Case Rep       Date:  2015-12-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.